Study of carbohydrate metabolism in patients with chronic obstructive pulmonary disease
https://doi.org/10.34651/0023-2149-2020-98-1-37-42
Abstract
We studied the carbohydrate metabolism in patients with chronic obstructive pulmonary disease (COPD) using glucose tolerance test (GTT) and were evaluated using this test to improve diagnosis of carbohydrate metabolism disorders (CMDS). Found that COPD patients with the exception of the risk factors listed in recommendations of who and the International diabetes Federation (IDF), GTT identifies NDU significantly more often than in the assessment of glucose of blood plasma on an empty stomach, this confirms the hypothesis put forward earlier by the authors of this work about the significant role of COPD in the pathogenesis of CMDS and in particular type 2 diabetes mellitus (DM2). This indicates the appropriateness of assigning COPD to the risk group for DM2, and, consequently, performing GTT in this cohort of patients. At the same time, GTT is a simple and fairly informative method of diagnosing CMDS and can be used as a screening method regardless of the fasting blood glucose level. It was also found that the prevalence of glucose tolerance disorders is much less common in Western Europe than in Eastern Europe, which is close to the values of our data.
About the Authors
V. I. Kobylyansky
Research Institute of Pulmonology, FMBA of Russia
Russian Federation
Vyacheslav I. Kobylyansky — MD, PhD, DSc, professor of the educational center of the research Institute of Pulmonology
115682, Moscow
Russian Federation
Vyacheslav I. Kobylyansky — MD, PhD, DSc, professor of the educational center of the research Institute of Pulmonology
115682, Moscow
O. Yu. Povarova
Federal Scientific and Clinical Center of the Federal Biomedical Agency of Russia
Russian Federation
115682, Moscow
Russian Federation
115682, Moscow
E. A. Soustova
Federal Scientific and Clinical Center of the Federal Biomedical Agency of Russia
Russian Federation
115682, Moscow
Russian Federation
115682, Moscow
References
1. Kobylyanskii V.I., Babadzhanova G.Yu., Suntsov Yu.I. Study of the relationship between chronic obstructive pulmonary pathology and type 2 diabetes. Terapevticheskii arkhiv. 2010;3;13–8. (in Russian)
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Workshop report (The 2006 report. is available on www.goldcopd.com. (see also UPDATED 2007)(Report 2019). https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS. pdf).
3. Tugud Dzh.Kh. Side effects of inhaled steroid therapy in asthma. Sibirskii meditsinskii zhurnal. 1996;7(2):34–9.
4. World Health Organization: Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and ins Complications. Geneva, World Health Organization,1999.
5. Algorithms for specialized medical care for patients with diabetes. Ed. Dedov I.I., Shestakova. Sakharnyi diabet. 2013;(6):5–118. (in Russian)
6. Porter M.H., Cutchins A, Fine J.B., Bai Y, DiGirolamo M. Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J. Lab. Clin. Med. 2002;139(3):140–6.
7. Tamakoshi K., Yatsuya H., Kondo et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int. J. Obes. Relat. Metab. Disord. 2003;27(4):443–9.
8. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D..Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.
9. Rahman I., Morrison D., Donaldson K., MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Crit. Care Med. 1996;54(4 (Pt 1):1055–60.
10. MacNee W., Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends. Mol. Med. 2001;7(2):55–62.
11. Cho N.H., Shaw J.E., Karuranga S.,at al al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 2018;138:271–81.
12. Unwin N., Shaw J., Zimmet P., Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia: the status on definition and intervention. Diabet Med. 2002;19(9):708–23.
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–69.
14. Stroup D., Berlin J.A., Morton S.A. at al. Meta-analysis of observational studies in epidemiology A proposal for reporting. J. Am. Med. Assoc. 2000;283(15):2008–12.
15. Tabak A.G., Herder C., Rathmann W., Brunner E.J., Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–90.
16. Szurkowska M., Szafraniec K., Gilis-Januszewska A. at al. Prevalence of the glucose metabolism disturbances in screening of adult inhabitants of Krakow. Przegl. Lek. 2006; 63(9):728–32.
17. Dedov I.I., Shestakova M.V., Galstyan G.R. Prevalence of type 2 diabetes in the adult population of Russia (nation studies). Sakharnyi diabet. 2016;2:104–12. (in Russian)
18. Dreval’ A.V., Misnikova I.V., Barsukov I.A. Eight models of screening for carbohydrate metabolism disorders. Problemy endo krinologii. 2008;54(6):3–7. (in Russian)
19. Harris M.I. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16(4):642–52.
20. Kaplan N.M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 1989;149(7):1514–20.
21. World health organization: definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part I: diagnosis and classification of diabetes mellitus. Geneva. 1999.
22. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.
23. Zimin Yu.V. Origin, diagnostic concept, and clinical significance of insulin resistance syndrome or metabolic syndrome X. Kardiologiya. 1998;6:71–81. (in Russian)
24. Harris M.I., Klein R., Welborn T.A. et al. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992;15: 815–9.
25. Ramlo-Halsted B.A., Edelman S.V. The natural history of type 2 diabetes. Implications for clinical practice. Prim. Care. 1999;26(4):771–89.
26. Ballard D.J., Humphrey L.L., Melton J. et al. Epidemiology of persistent proteinuria in tipe II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes.1988;37(4):405–12.
27. Kobylyanskii V.I., Babadzhanova G.Yu., Suntsov Yu.N. et al. Connection of chronic inflammatory diseases of the lungs and diabetes mellitus. XII national Congress on respiratory diseases. Kazan. 2007:59. (in Russian)
28. Oudijk E., Lammers J., Koenderman l. et al. Systemic inflammation in chronic obstructive pulmonary disease. Eur. Respir. J. 2003;22:5S–13S.
29. Dedov I.I., Chazova T.E., Suntsov Yu.I. Epidemiology of diabetes mellitus. M., 2003:47–51. (in Russian)
Review
For citations:
Kobylyansky V.I., Povarova O.Yu., Soustova E.A. Study of carbohydrate metabolism in patients with chronic obstructive pulmonary disease. Clinical Medicine (Russian Journal). 2020;98(1):37-42. (In Russ.) https://doi.org/10.34651/0023-2149-2020-98-1-37-42
Views:
496
Email this article 